A new 3-year clinical study on PHYTO SOYA® demonstrating the total safety of
the treatment!
For more than 15 years now, the pharmaceutical laboratories, ARKOPHARMA, have invested in
numerous studies to support and demonstrate the benefits of PHYTO SOYA® - a unique proprietary
and exclusive extract - as an alternative approach to treat and reduce the symptoms of menopause.
Less then 8 years after its first multicentre, double-blind, randomised placebo controlled study was
published in MENOPAUSE, the Journal of The North American Menopause Society - Volume 9 Number 5 2002
“Effect of a standardized soy extract on hot flushes - Drapier-Faure/Chantre/Marès” - demonstrating
the efficacy of PHYTO SOYA®, ARKOPHARMA has recently released and published its last
3-year study demonstrating the safety of this specialised product.
This latest clinical study was based on the daily administration of 70mg of PHYTO SOYA®
specific standardised extract of soya isoflavones (5% Daidzein and 2% Genistein) to 197 women (395 postmenopausal
women included) to assess in the long-term the absence of risk in the endometrium and breast.
These results prove that PHYTO SOYA® isoflavones do not have any effect on mammary
density nor induce any hyperplasia of the endometrium.
PHYTO SOYA® remains the main natural alternative based on clinical studies, proving
that PHYTO SOYA® standardised isoflavones extract is scientifically recognised for
its beneficial effects on the symptoms of menopause and its real contribution towards maintaining a
good quality of life for menopausal women.
The new and recently-published studies demonstrate once again that PHYTO SOYA® is a genuine natural
alternative to conventional treatments for menopause with an excellent benefit/risk ratio.
The results of these studies are only applicable to PHYTO SOYA® specific extract rich in Daidzein.
They cannot be extrapolated to any other product.
or purchase from good pharmacies and health stores including
Dis-Chem Pharmacies nationwide
